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Big dataThere is on-going effort in the biomedical research community to leverage Next Generation Sequencing (NGS)
technology to identify genetic variants that affect our health. The main challenge facing researchers is getting
enough samples from individuals either sick or healthy – to be able to reliably identify the few variants that
are causal for a phenotype among all other variants typically seen among individuals. At the same time, more
and more individuals are having their genome sequenced either out of curiosity or to identify the cause of an ill-
ness. These individualsmay beneﬁt from of away to view and understand their data. QIAGEN's Ingenuity Variant
Analysis is an online application that allows userswith andwithout extensive bioinformatics training to incorpo-
rate information from published experiments, genetic databases, and a variety of statistical models to identify
variants, from a long list of candidates, that are most likely causal for a phenotype as well as annotate variants
with what is already known about them in the literature and databases. Ingenuity Variant Analysis is also an in-
formation sharing platformwhere usersmay exchange samples and analyses. The EmpoweredGenome Commu-
nity (EGC) is a new program in which QIAGEN is making this on-line tool freely available to any individual who
wishes to analyze their own genetic sequence. EGC members are then able to make their data available to other
Ingenuity Variant Analysis users to be used in research. Here we present and describe the Empowered Genome
Community in detail. We also present a preliminary, proof-of-concept study that utilizes the 200 genomes cur-
rently available through the EGC. The goal of this program is to allow individuals to access and understand
their own data as well as facilitate citizen–scientist collaborations that can drive research forward and spur qual-
ity scientiﬁc dialogue in the general public.
© 2015 Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
There is on-going effort in the biomedical research community to le-
verage Next Generation Sequencing (NGS) technology to identify
genetic variants that affect our health. In analyzing NGS datasets, how-
ever, researchers face at least two key challenges: i) accessing enough
samples to reliably detect that a genetic variant is unique to a group of
affected individuals versus healthy controls and ii) identifying, the caus-
al variants for the phenotype in affected individuals, from a long list of
sequence variants.
The latter typically involves ﬁltering a list of sequence variants by re-
moving those that are unlikely to have any biological consequence —
often determined by their high frequency in the general population or
if they are non-coding or synonymous variants. At the same time, one
generally focuses on the variants that have characteristics similar to a
known pathological mutation or occur in a gene known to be part of
the disease pathology. Even when this information is available for the(K. Wendelsdorf),
icle under the CC BY-NC-ND license (variants being considered, it is scattered among disparate resources
such as peer-reviewed literature, experimental databases, and public
sequence banks. Bringing these sources together in a single analysis re-
quires time, programing experience, and big data management skills
beyond those of most individual researchers.
QIAGEN's Ingenuity Variant Analysis is an on-line tool that is used to
address this challenge of ﬁltering variant lists down to the best causal
candidates. The Variant Analysis interface provides simultaneous access
to information from N10million ﬁndings, including peer reviewed pub-
lications and biological databases such as 1000Genomes,National Heart
Lung and Blood Initiative's (NHLBI) Exome Variant Server (EVS), TCGA,
OMIM (Hamosh et al., 2005), COSMIC (Forbes et al., 2015), DrugBank
(Law et al., 2014), and others. It is designed to bring biological informa-
tion from these sources together and construct sophisticated genetic ﬁl-
tering criteria to identify and sequentially eliminate those variants that
are likely inconsequential, narrowing to a small set most likely to cause
the disease/abnormality. Once, these relevant variants have been iden-
tiﬁed the same interface can be used to construct testable mechanistic
hypotheses based on reported biological relationships between genes/
variants and the phenotypes. Users can also share these ﬁndings and
analyses directly with colleagues and potential collaborators.http://creativecommons.org/licenses/by-nc-nd/4.0/).
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with access to all current knowledge about a list of variants, researchers
are often in need of additional samples in order to detect disease-
causing variants with b100% penetrance as well as those that may be
common in an under-sampled healthy subpopulation. Such additional
samples are hard to ﬁnd.
An increasing number of individuals are opting to get their genetic
variants through direct-to-consumer (DTC) genotyping such as
23andMe as well as programs such as Illumina's UYG (http://www.
illumina.com/company/events/understand-your-genome.html) and
Harvard's Personal Genome Project (http://www.personalgenomes.
org). Often it is curiosity or the need to diagnose a health condition
that motivates consumers to directly obtain this genetic information.
However, once it is received, they may lack the bioinformatics skills
and resources to make sense of their own datasets. Or they may want
to connect with trained scientists who may be able to use their data to
inform a disease etiology. Such individuals would greatly beneﬁt from
a platform to make sense of their data and effectively share it with re-
searchers who can use it to expedite discoveries that lead to treatments
and diagnostics.
Here,we introduceQIAGEN's EmpoweredGenomeCommunity. This
is a program to help people make their own well-sequenced genomes
more scientiﬁcally useful. In short, we are making Ingenuity Variant
Analysis freely available for any individual to explore their own genetic
information and share it with researchers in the on-line interface. This
will i) allow individuals to view and explore their own data without
the need for bioinformatics skills, ii) help them better understand the
standard genomic interpretation process and its caveats, iii) enable
them to securely share their data with speciﬁc researchers of their
choice, as well as iv) create a resource of additional phenotyped ge-
nomes for researchers.2. Results & discussion
2.1. A user-friendly tool for genomic analysis and exploration
Ingenuity Variant Analysis is an online application to ﬁlter variants
from NGS data and identify a plausible causal pathway from variant to
diseases. Users with and without extensive bioinformatics training are
able to use the interface to incorporate published experimental observa-
tions, variant frequencies across different databases, and a variety of sta-
tistical models to deﬁne ﬁltering criteria andmechanistic hypotheses. A
typical data analysis workﬂow is outlined in Fig. 1.Fig. 1. Variant Anal(a)Users upload a list of all possible variants – often several thousands
to millions – either as an individual sample or as groups of related or un-
related cases/controls samples. (b) Construct a custom ﬁlter cascade that
brings in different pieces of information to sequentially eliminate candi-
date variants down to a short list based on different criteria such as:
• Conﬁdence ﬁlter: data quality such as the read depth at a variant
position.
• Common variants ﬁlter: frequency of the variant in the general pop-
ulation determined by its frequency across different sequence da-
tabases (1000 genomes project, NHLBI exomes, and Allele
Frequency Community, hosted by QIAGEN).
• Predicted deleterious ﬁlter: Whether the variant is likely to be
pathogenic based on experimental observations in the literature,
ACMG guidelines, damaging sequence characteristics (truncat-
ing, frame-shift, etc.) deﬁned by in silico modeling algorithms
(SIFT, PolyPhen, MaxEntScan, and others), and more.
• Genetic analysis ﬁlter: whether it is of a genotype one would expect
of the disease-causing variant, for example, homozygous in affected
individual if the trait is recessive.
• Statistical association ﬁlter: whether, in a multi-sample study, it is sig-
niﬁcantly associated with an affected case group versus a group of
healthy controls.
• Biological context ﬁlter: whether the variant occurs in a gene that has
been previously implicated in a user-speciﬁed disease/phenotype or
shown to affect a speciﬁc physiological process.
Users startwith a defaultﬁlter cascade and canmodify theﬁlters and
parameters to create an analysis best suited for their speciﬁc scientiﬁc
question(s). The result is the short list of variants that ﬁt all of the
criteria set in each ﬁlter. (c) For this shortlist of variants, one can then
access peer-reviewed and manually curated experimental information
about known gene–gene interactions to identify biological pathways
between a mutated gene and a speciﬁc phenotype. (d) In the same in-
terface, samples as well as analyses and the ﬁlter cascade can be shared
with colleagues to view in their own account. This allows users to share/
pool samples, collaborate on constructing analyses, aswell as effectively
communicate about any actionable results.
2.2. Empowered genome community — how it works
As registered members of the Empowered Genome Community
(EGC), individuals who have their genomes sequenced can upload andysis workﬂow.
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can also share it with researchers within the application to serve either
as cases or controls. With this access, these individuals can explore the
DNA sequence variants that they have and learn the observed effect of
these variants in published studies.
Members of the EGC have the option to share their sequence data
and health information within Ingenuity Variant Analysis in one of
three ways:
i) Broadly: an EGC member ﬁlls out a health survey and makes the
health information and all uploaded sequence data available to
all Ingenuity Variant Analysis users. This data is viewable by
QIAGEN, but is not sold. It is made freely available on the Ingenu-
ity Variant Analysis platform to researchers who request access
to it.
ii) Privately: an EGCmember shares a speciﬁc subset of their genetic
variants or health information with speciﬁc researchers with
whom they are in contact. The data is not viewable by QIAGEN.
iii) Just genetic variants and no phenotypic data: an EGCmember may
submit their variants to the Allele Frequency Community (AFC).
This is a community of researchers and laboratories that share
anonymized, pooled allele frequency statistics. It is hosted by In-
genuity Variant Analysis and is currently composed of over
100,000 integrated, anonymized human exome/genome variant
datasets. This resource is freely available to anyone to annotate
and ﬁlter their variants with AFC frequencies.
The EGC beneﬁts researchers by giving them access to any of the
‘broadly’ shared genomeswith speciﬁc phenotypes. Researchers submit
the number of samples they need and the phenotypes that must be as-
sociated. EGC samples thatﬁt the speciﬁed phenotypeswill then be pro-
vided to them in their account at which point they can use the donated
samples in their case–control studies. In addition, they have a platform
withwhich to collaborate and privately exchange datawith speciﬁc EGC
members that they are in contact with.
2.3. Value of EGC: access, educate, collaborate
We see the value of the EGC as being three-fold:
Access: with Ingenuity Variant Analysis, EGC members are able to
use the interface to incorporate published experimental observations,
variant information from different databases, and various statistical
models to contextualize and identify the potential relevance of their ge-
netic variants. This is all possible without the need for programming ex-
perience and big data management skills. In this way, EGCmembership
allows individuals to view, understand, and explore their own data in a
way that is not yet available to them.
Educating the public: the EGC provides a means for non-scientists to
learn about the caveats of the genome interpretation process. In using
the ﬁlter cascade and application tutorials to ﬁlter and explore their
own variants, individuals will be exposed to the concept of variant call
conﬁdence and sequencing data quality. They will also be able to see
the variety of experimental evidence and criteria used to conclude
that a genetic variant ismedically relevant. Importantly, theywill quick-
ly see how changes to those criteria, through ﬁlter cascade modiﬁca-
tions, can alter results. This is a small step towards educating the
public to be more discerning about claims posed by pharmaceutical
companies, DTC sequencing companies, and themedia about the impact
of speciﬁc mutations — which will likely increase as more genomic in-
terpretation services become available.
Fostering collaboration: through the EGC,members control their own
data allowing them to privately view their data on a secure platform
and, at the same time,make it scientiﬁcally useful by sharing itwith spe-
ciﬁc researchers of their choice. The sharing platform allows them to,
not only exchange data, but also better understand and communicatewith scientists about what is being donewith their data. This is because
the researcher can later share any analyses done with the member's
sample for viewing in the interface. This continued communication al-
lows for more active collaboration as both parties desire. EGC members
have complete control over the amount of data they share andwho they
entrust to see it.
3. ‘Open’ analysis of EGC data gives insight into genetic causes of
hypercholesterolemia
There are currently ~200 phenotyped genomes in the broadly
shared pool of EGC genomes –where the sequenced individuals agreed
to share the data as well as provide phenotypic health information. The
most commonhealth phenotype is hypercholesterolemia. As a proof-of-
concept we sought to identify variants speciﬁc to hypercholesterolemia
using these donated samples. Speciﬁcally, we have taken 12,331 shared
genomes (36 cases, 95 controls). The analysis was limited to exonic re-
gions of the samples yielding an initial set of 271,840 total variants
spanning 18,888 genes. The following ﬁlters were then applied:Variantswere kept only if theymet the call conﬁdence criteria of a call
quality N=20 in a case or control sample andoccur outside the top 5%
most exonically variable 100basewindows inhealthypublic genomes
(1000 genomes). Of these, we excluded variants that are observed
with an allele frequency N=5% of the genomes in the 1000 genomes
project (http://www.1000genomes.org), the public Complete Geno-
mics genomes, the NHLBI ESP exomes, or the Allele Frequency Com-
munity (http://www.allelefrequencycommunity.org). Of these we
only kept a variant in the list if it met one of the following criteria
for predicted deleteriousness: i) the variant was experimentally ob-
served to be associated with a ‘Pathogenic’ or ‘Possibly Pathogenic’
phenotype according to ACMG guidelines, ii) The variant demonstrat-
ed gain of function effect on the gene according to a published study,
iii) the variant causes a frameshift, in-frame indel, or stop codon
change, iv) is a missense mutation that is not predicted to be innocu-
ous by SIFT or Polyphen-2, v) the variant disrupts a splice site up to 2.0
bases into an intron, or vi) is predicted to disrupt splicing by
MaxEntScan (Burge et al., 2004). The Statistical Association ﬁlter was
then applied to the remaining variants to conduct a SKAT-O test that
identiﬁed genes with a signiﬁcant variant burden in either the case
or control groupwith a burden test p-value b=0.01.We then applied
a biological context ﬁlter to identify and keep burdened genes that
have been previously associated with ‘Hypercholesterolemia’ or ‘cho-
lesterol metabolism’ according to the Ingenuity Knowledge Base.
The ﬁnal result was a set of 7 variants across 2 genes: TF and LRP5.
Interestingly, LRP5 (lipoprotein receptor-related protein) bears a signif-
icant burden among the healthy control samples indicating that its mu-
tationmay be protective against hypercholesterolemia. Speciﬁcally, 5 of
the identiﬁed 7 of the variants occur in the LRP5 gene across 16 healthy
controls, but none of the hypercholesterolemic cases. In particular,
c.1999G N A (p.Val667Met) is an exonic missense variant in LRP5
whose frequency is signiﬁcantly higher in the control group, occurring
in 12 controls and 0 cases (p-value b 0.05). Though this variant has
not been linked to hypercholesterolemia in humans, it has been
shown to affect cholesterol metabolism in mouse models (Fujino et al.,
2002). The other 4 variants in LRP5 (c.632G N A(p.W211*), c.1337A N
G(p.N446S), c.16A N G(p.T6A), c.2009_2010insC(p.T1252fs*30)) each
occurs in only 1 individual.
Of the 2 variants that occur in TF (transferrin), 1 occurs in only 2
cases and the other in only 1 case. Though TF, as a gene, bears a signiﬁ-
cant variant burden in the hypercholesterolemic case group, these are
the only 2 variants that have been previously linked to hypercholester-
emia and neither occurs at a signiﬁcantly higher frequency in the case
group vs. the control group.
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Variant Analysis. All are invited to visit the study and explore this pre-
liminary ﬁnding as well as reﬁne the ﬁndings with their own insights
on hypercholesterolemia etiology, sample structure, and validation.4. Concluding remarks
Critical to personalized medicine research is the ability to identify
the relevant genetic variants in an individual. Having enough samples
to detect a variant in the affected population is a key challenge. This
‘sample abundance’ challenge can be partly reduced by platforms that
enable individuals to share their health and biological data with re-
searchers/clinicians in a useful form such that the data/information
can be leveraged tomakemedically relevant discoveries faster.With In-
genuity Variant Analysis we see an opportunity to help individuals ac-
cess their own data and, at the same time, allow them to readily share
it with needy researchers in a ready-to-use form.
The EGC is quite an investment on the part of QIAGEN in terms of
compiling, storing and securing the data to provide this free service.
We have taken on these responsibilities because it is our philosophy
that patients have a right to access and understand their own data.
We also believe it is important for commercial and governmental enti-
ties to play a role in facilitating citizen–scientist collaborations that
can drive research forward and spur quality scientiﬁc dialogue in the
general public.More information
Where can I go to get my sequence?
As part of Illumina's Understand Your Genome Program: http://
www.illumina.com/company/events/understand-your-genome.html
Become a member of the Personal Genome Project: http://www.
personalgenomes.org/harvard/sign-upHow do I join the EGC?
Once you have your genetic variant data in .vcf format you can reg-
ister at the EGCwebsite to upload your data and start analyzing it. Please
contact your sequencing service to ﬁnd out how best to receive your
data in a.vcf format.Who will see my private data?
Only you, and anyone you choose to share it with.Do I have to share my private data?
No. If you wish, you can analyze your own genome, and any
genome(s) shared to you by others, without sharing yours.
Will QIAGEN sell, rent, or mine my data?
QIAGENwill not sell or rent any data obtained as part of the EGC.We
don't mine any private data, or keep it ourselves. If you actively opt to
join the Allele Frequency Community (AFC), then your sequence data
will be used to update the anonymized and pooled statistics for variants
in the AFC.
How can I view and affect the hypercholesterolemia study?
Visit the Variant Analysis web page to create an account. Once in the
application, you can click on the ‘Publications’ tab to open, view, and
modify the study.
Links
Ingenuity Variant Analysis: http://www.ingenuity.com/products/
variant-analysis
Allele Frequency Community: www.allelefrequencycommunity.
com
Empowered Genome Community: https://www.
qiagenbioinformatics.com/empowered/
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